Case report: 217 COVID vaccine doses haven’t harmed man’s immune system – University of Minnesota Twin Cities

CARB-X today announced funding for its 100th project addressing antimicrobial resistance (AMR).

The $1.06 million award will help the Hemholtz Institute for Pharmaceutical Research Saarland (HIPS), of Saarbrucken, Germany, develop a new class of small-molecule inhibitors of bacterial sliding clamp, a pivotal component of DNA replication machinery that has not previously been targeted. The novel compounds have shown promising antibacterial activity against several pathogens that cause community-acquired bacterial pneumonia (CABP).

Lower respiratory tract infections, including CABP, are estimated to have killed 2.6 million people globally in 2019, more than 400,000 of whom died from infections caused by antibiotic-resistant bacteria.

"With this 100thproject, we are doubling-down on our support of novel approaches to deliver antibiotics that clinicians and patients need," CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) R&D chief Erin Duffy, PhD, said in a press release. "If successful, the HIPS project will offer a workhorse antibiotic for community-acquired infections that will also take the pressure off antibiotics in the [World Health Organization] model list of essential medicines."

Since its founding in 2016, CARB-X has played a critical role in efforts to boost the pipeline for new antibacterials and other products targeting drug-resistant bacteria, awarding $452.6 million for early-stage development of vaccines, diagnostic, antibiotics, and other therapies. Eighteen of its 100 projects have made it into first-in-human trials, 12 remain in clinical development, and 2 diagnostics have reached the market.

"When CARB-X started in 2016, the antibacterial pre-clinical pipeline looked promising but vulnerable," said CARB-X Executive Director Kevin Outterson, JD. "Even the teams with the most impactful ideas lacked the capital and support needed to advance their R&D products towards patients. CARB-X stood in the gap, and, eight years later, we have clear proof that our model is working."

Read the original post:

Case report: 217 COVID vaccine doses haven't harmed man's immune system - University of Minnesota Twin Cities